Ionis Pharmaceuticals Inc
IONS42.660USD
+0.180+0.42%
Market hours （ET）Quotes delayed by 15 min
6.79BMarket Cap
LossP/E TTM
More Details of Ionis Pharmaceuticals Inc Company
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Company Info
Ticker SymbolIONS
Company nameIonis Pharmaceuticals Inc
IPO dateMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Number of employees1069
Security typeOrdinary Share
Fiscal year-endMay 17
Address2855 Gazelle Court
CityCARLSBAD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92010
Phone17609319200
Websitehttps://www.ionis.com/
Ticker SymbolIONS
IPO dateMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.82K
-0.64%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
89.49K
-10.05%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
-16.75%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
+12.65%
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.82K
-0.64%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
89.49K
-10.05%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Other
51.29%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Other
51.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
71.14%
Hedge Fund
16.49%
Investment Advisor/Hedge Fund
16.46%
Research Firm
2.04%
Private Equity
1.59%
Pension Fund
1.12%
Individual Investor
0.81%
Bank and Trust
0.66%
Sovereign Wealth Fund
0.28%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Two Sigma Investments, LP
3.78M
2.37%
+1.51M
+66.38%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
Tema Neuroscience and Mental Health ETF
3.69%
ARK Genomic Revolution ETF
3.41%
Virtus LifeSci Biotech Products ETF
2.32%
SPDR S&P Biotech ETF
1.56%
WisdomTree BioRevolution Fund
1.35%
Tema Heart & Health ETF
1.08%
Direxion Daily S&P Biotech Bull 3X Shares
1.01%
Capital Group US Small and Mid Cap ETF
0.92%
iShares Health Innovation Active ETF
0.88%
Franklin Genomic Advancements ETF
0.83%
View more
Tema Neuroscience and Mental Health ETF
Proportion3.69%
ARK Genomic Revolution ETF
Proportion3.41%
Virtus LifeSci Biotech Products ETF
Proportion2.32%
SPDR S&P Biotech ETF
Proportion1.56%
WisdomTree BioRevolution Fund
Proportion1.35%
Tema Heart & Health ETF
Proportion1.08%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.01%
Capital Group US Small and Mid Cap ETF
Proportion0.92%
iShares Health Innovation Active ETF
Proportion0.88%
Franklin Genomic Advancements ETF
Proportion0.83%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
